Page 4 - Julien Valton News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress

Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

North carolinaUnited statesFrance generalBruxelles capitaleNew yorkArthur strilJulien valtonMaria feolaEduardo seclenAshleyr robinsonPatricia sosa navarroGene therapy programSecurities exchange commissionSenior scientist team leaderCellectis the company euronext growthEuropean society of gene

Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress

Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

North carolinaUnited statesFrance generalBruxelles capitaleNew yorkPatricia sosa navarroMaria feolaArthur strilJulien valtonAshleyr robinsonEduardo seclenCellectis the company euronext growthEuropean society of geneSecurities exchange commissionSenior scientist team leaderEuronext growth

Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress - Cellectis (NASDAQ:CLLS)

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,

North carolinaUnited statesNew yorkFrance generalBruxelles capitalePatricia sosa navarroArthur strilMaria feolaEduardo seclenJulien valtonAshleyr robinsonSecurities exchange commissionEuropean society of geneSenior scientist team leaderCellectis the companyEuropean society

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesNew yorkNorth carolinaAshleyr robinsonSven krackerJulien valtonArthur strilCroix jarryHospitalier universitaire ouestPatricia sosa navarroLaboratory of inflammatory responsesCellectis the company euronext growthCellectis incMethods clinical developmentAtip avenir team

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell

France generalNorth carolinaUnited statesNew yorkHospitalier universitaire ouestCroix jarryArthur strilSven krackerAshleyr robinsonPatricia sosa navarroJulien valtonSecurities exchange commissionCellectis incLaboratory of human lymphohematopoiesisMethods clinical developmentBiotherapy clinical investigation center